Cargando…

Impact of heavy smoking on the benefits from first-line EGFR-TKI therapy in patients with advanced lung adenocarcinoma

Smoking is a risk factor for nonsmall cell lung carcinoma (NSCLC) and is associated with a lower response to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI). The purpose of this study is to examine the impact of the smoking status on the benefits from first-line EGFR-TKI in NS...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Ping, Nie, Xin, Bie, Zhixin, Li, Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5851738/
https://www.ncbi.nlm.nih.gov/pubmed/29489642
http://dx.doi.org/10.1097/MD.0000000000010006
_version_ 1783306446286356480
author Zhang, Ping
Nie, Xin
Bie, Zhixin
Li, Lin
author_facet Zhang, Ping
Nie, Xin
Bie, Zhixin
Li, Lin
author_sort Zhang, Ping
collection PubMed
description Smoking is a risk factor for nonsmall cell lung carcinoma (NSCLC) and is associated with a lower response to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI). The purpose of this study is to examine the impact of the smoking status on the benefits from first-line EGFR-TKI in NSCLC patients with EGFR mutation. This was a retrospective study of 159 patients with advanced NSCLC treated at the Beijing Hospital between January 2011 and December 2016. The follow-up was censored on December 2017. EGFR mutation status, smoking (nonsmoker vs <30 packs/year (light smoker) vs ≥30 packs/year (heavy smoker)), treatment, treatment response, and progression-free survival (PFS) were collected from the charts. Median follow-up was 10.0 (1.0–36.6) months. Response rate was lower in heavy smokers compared with nonheavy smokers (19.0% vs 71.7%, P < .001). There was no difference in PFS between nonsmokers (median, 10.5 months) and light smoker (median, 11.0 months), and these 2 groups were pooled together. PFS was longer in nonheavy smokers compared with heavy-smokers (median, 10.7 vs 6.0 months, P < .001). Smoking ≥ 30 packs/year (HR = 2.48, 95% CI: 1.55–3.98, P < .001) was associated with PFS. In patients with advanced NSCLC, the benefits and PFS of EGFR-TKI were better for nonheavy smokers than for heavy smokers.
format Online
Article
Text
id pubmed-5851738
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-58517382018-03-21 Impact of heavy smoking on the benefits from first-line EGFR-TKI therapy in patients with advanced lung adenocarcinoma Zhang, Ping Nie, Xin Bie, Zhixin Li, Lin Medicine (Baltimore) 5700 Smoking is a risk factor for nonsmall cell lung carcinoma (NSCLC) and is associated with a lower response to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI). The purpose of this study is to examine the impact of the smoking status on the benefits from first-line EGFR-TKI in NSCLC patients with EGFR mutation. This was a retrospective study of 159 patients with advanced NSCLC treated at the Beijing Hospital between January 2011 and December 2016. The follow-up was censored on December 2017. EGFR mutation status, smoking (nonsmoker vs <30 packs/year (light smoker) vs ≥30 packs/year (heavy smoker)), treatment, treatment response, and progression-free survival (PFS) were collected from the charts. Median follow-up was 10.0 (1.0–36.6) months. Response rate was lower in heavy smokers compared with nonheavy smokers (19.0% vs 71.7%, P < .001). There was no difference in PFS between nonsmokers (median, 10.5 months) and light smoker (median, 11.0 months), and these 2 groups were pooled together. PFS was longer in nonheavy smokers compared with heavy-smokers (median, 10.7 vs 6.0 months, P < .001). Smoking ≥ 30 packs/year (HR = 2.48, 95% CI: 1.55–3.98, P < .001) was associated with PFS. In patients with advanced NSCLC, the benefits and PFS of EGFR-TKI were better for nonheavy smokers than for heavy smokers. Wolters Kluwer Health 2018-03-02 /pmc/articles/PMC5851738/ /pubmed/29489642 http://dx.doi.org/10.1097/MD.0000000000010006 Text en Copyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nd/4.0 This is an open access article distributed under the Creative Commons Attribution-NoDerivatives License 4.0, which allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to the author. http://creativecommons.org/licenses/by-nd/4.0
spellingShingle 5700
Zhang, Ping
Nie, Xin
Bie, Zhixin
Li, Lin
Impact of heavy smoking on the benefits from first-line EGFR-TKI therapy in patients with advanced lung adenocarcinoma
title Impact of heavy smoking on the benefits from first-line EGFR-TKI therapy in patients with advanced lung adenocarcinoma
title_full Impact of heavy smoking on the benefits from first-line EGFR-TKI therapy in patients with advanced lung adenocarcinoma
title_fullStr Impact of heavy smoking on the benefits from first-line EGFR-TKI therapy in patients with advanced lung adenocarcinoma
title_full_unstemmed Impact of heavy smoking on the benefits from first-line EGFR-TKI therapy in patients with advanced lung adenocarcinoma
title_short Impact of heavy smoking on the benefits from first-line EGFR-TKI therapy in patients with advanced lung adenocarcinoma
title_sort impact of heavy smoking on the benefits from first-line egfr-tki therapy in patients with advanced lung adenocarcinoma
topic 5700
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5851738/
https://www.ncbi.nlm.nih.gov/pubmed/29489642
http://dx.doi.org/10.1097/MD.0000000000010006
work_keys_str_mv AT zhangping impactofheavysmokingonthebenefitsfromfirstlineegfrtkitherapyinpatientswithadvancedlungadenocarcinoma
AT niexin impactofheavysmokingonthebenefitsfromfirstlineegfrtkitherapyinpatientswithadvancedlungadenocarcinoma
AT biezhixin impactofheavysmokingonthebenefitsfromfirstlineegfrtkitherapyinpatientswithadvancedlungadenocarcinoma
AT lilin impactofheavysmokingonthebenefitsfromfirstlineegfrtkitherapyinpatientswithadvancedlungadenocarcinoma